VCEL vs. DNLI, KYMR, TWST, CGON, APGE, SANA, RXRX, DNA, ACLX, and BEAM
Should you be buying Vericel stock or one of its competitors? The main competitors of Vericel include Denali Therapeutics (DNLI), Kymera Therapeutics (KYMR), Twist Bioscience (TWST), CG Oncology (CGON), Apogee Therapeutics (APGE), Sana Biotechnology (SANA), Recursion Pharmaceuticals (RXRX), Ginkgo Bioworks (DNA), Arcellx (ACLX), and Beam Therapeutics (BEAM). These companies are all part of the "biological products, except diagnostic" industry.
Denali Therapeutics (NASDAQ:DNLI) and Vericel (NASDAQ:VCEL) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, community ranking, institutional ownership and dividends.
In the previous week, Vericel had 1 more articles in the media than Denali Therapeutics. MarketBeat recorded 30 mentions for Vericel and 29 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.72 beat Vericel's score of 0.37 indicating that Vericel is being referred to more favorably in the news media.
92.9% of Denali Therapeutics shares are owned by institutional investors. 7.9% of Denali Therapeutics shares are owned by insiders. Comparatively, 5.2% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Vericel has a net margin of 0.22% compared to Vericel's net margin of -36.51%. Denali Therapeutics' return on equity of 0.21% beat Vericel's return on equity.
Denali Therapeutics presently has a consensus target price of $40.22, suggesting a potential upside of 119.67%. Vericel has a consensus target price of $46.80, suggesting a potential downside of 2.70%. Given Vericel's higher possible upside, equities research analysts clearly believe Denali Therapeutics is more favorable than Vericel.
Denali Therapeutics has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.74, indicating that its share price is 74% more volatile than the S&P 500.
Denali Therapeutics received 103 more outperform votes than Vericel when rated by MarketBeat users. Likewise, 67.43% of users gave Denali Therapeutics an outperform vote while only 62.34% of users gave Vericel an outperform vote.
Vericel has lower revenue, but higher earnings than Denali Therapeutics. Vericel is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Vericel beats Denali Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Vericel News Delivered to You Automatically
Sign up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
